

## 別添5

## 研究成果の刊行に関する一覧表

## 書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
岡田浩一、他	最新ガイドラインに基づく腎・透析診療指針2023-24序文、腎画像診断	岡田浩一	最新ガイドラインに基づく腎・透析 診療指針2023-24	総合医学社	東京	2023	22
岡田浩一、他	第13章高齢者CKD	丸山彰一	エビデンスに基づくCKD診療ガイドライン2023	東京医学社	東京	2023	149
岡田浩一 黒澤陽一、成田一衛	第1章3CKD：標準治療の理解と実践 薬剤性腎障害	南学正臣、高野秀樹 岡田浩一	腎臓内科診療の綱 最新ガイドラインに基づく腎・透析 診療指針 2023-24	中外医学社 総合医学社	東京 東京	2023 2023	17 63-69
藤井美里、成田一衛	MPGN (C3腎症) : わかってきた新しい病型分類と概念	南学正臣、高野秀樹	腎臓内科診療の綱	中外医学社	東京	2023	129-134
旭浩一	尿検査（蛋白尿・血尿）	岡田浩一	最新ガイドラインに基づく腎・透析診療指針	総合医学社	東京	2023	7-13
葉原孝成	薬剤性腎障害	福井次矢、高木 誠、小室一成	今日の治療指針 2024年版	医学書院	東京	2024	616-618
葉原孝成	がんと腎臓	今井圓裕、丸山彰一、猪阪善隆	腎臓内科レジデンントマニュアル	医学書院	東京	2023	641-649
川嶋聰子、要伸也	ANCA検査のピットフォール		SRL宝函44(2)			2023	42-44

## 雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Okada H, et al.	Development of a prognostic risk score to predict early mortality in incident elderly Japanese hemodialysis patients.	PLoS One.	19(4)	e0302101.	2024

Yano Y, et al.	Kidney outcomes associated with hematuria and proteinuria trajectories among patients with IgA nephropathy in real-world clinical practice: The Japan Chronic Kidney Disease Database	Nephrology	29	65–75	2023
岡田浩一	腎不全患者の予後と予測式の開発	日本腎臓学会誌	65	876–879	2023
岡田浩一、他	腎臓病領域における20年のあゆみと今後の展望	日本内科学会特別号 創立120周年記念誌	209		2023
Matsuzaki K, et al.	Current treatment status of IgA nephropathy in Japan: a questionnaire survey.	Clin Exp Nephrol	(in press)	(in press)	(in press)
Yamamoto T, Kasahara M, Ueshima K, Uemura S, Kashihara N, Kimura K, Ono T, Shoji T, Mima A, Mukoyama M, Saito Y.	Multicenter randomized controlled trial of intensive uric acid lowering therapy for CKD patients with hyperuricemia: TARGET-UA.	Clin Exp Nephrol.			2024 Online ahead of print.
Kishi S, Nakashima T, Goto T, Nagasawa H, Brooks CR, Okada H, Tamura K, Nakano T, Narita I, Maruyama S, Yano Y, Yokoo T, Wada T, Wada J, Nanogaku M, Kashihara N.	Association of serum magnesium levels with renal prognosis in patients with chronic kidney disease.	Clin Exp Nephrol.			2024 Online ahead of print.
Yusei O, Nagasawa H, Nakagawa N, Terawaki S, Moriwaki T, Itano S, Kishi S, Sasaki T, Kashihara N, Otomo T.	A case series of Fabry diseases with ChroKD in Japan.	Clin Exp Nephrol.			2024 Online ahead of print.
Kanda E, Epureanu BI, Adachi T, Sasaki T, Kashihara N.	Mathematical expansion and clinical application of chronic kidney disease stage as vector field.	PLoS One.	19(3)	e0297389.	2024

Kishi S, Nagas u H, Kidokoro K, Kashihara N.	Oxidative stress an d the role of redoxrol. signalling in chro nic kidney disease.	Nat Rev Nephrol. 20(2)	101–119.	2024	
Yanagita M, et al.	Clinical questions and good practice statements of clinic al practice guideli nes for management of kidney injury du ring anticancer dru g therapy 2022.	Clin Exp Nep 28(2)	85–122.	2024	
Sugawara Y, Kae nda E, Ohsugi M, Ueki K, Kas hihara N, Nang aku M.	eGFR slope as a sur rogate endpoint for end-stage kidney d isease in patients with diabetes and e GFR > 30 mL/min/1.7 3 m <sup>2</sup> in the J-DREAM S cohort.	Clin Exp Nep 28(2)	144–152.	2024	
Kanda E, Epure anu BI, Adachin T, Sasaki T, Kashihara N.	New marker for chro nic kidney disease progression and mor tality in medical-w ord virtual space.	Sci Rep. 14(1)	1661.	2024	
Hirano A, Kado ya H, Yamanouc hi Y, Kishi S, Sasaki T, Kas hihara N.	IL-1 $\beta$ may be an in dicator of peritone al deterioration af ter healing of peri toneal dialysis-ass ociated peritoniti s.	BMC Nephrol. 24(1)	374.	2023	
Li Y, Fujii M, Ohno Y, Ikeda A, Godai K, akamura Y, Aka gi Y, Yabe D, Tsushita K, Kaya shi N, Kam ide K, Kabayame a M.	Lifestyle factors a ssociated with a ra pid decline in the estimated glomerula r filtration rate o ver two years in ol der adults with typ e 2 diabetes—Eviden ce from a large na tional database in J apan.	PLoS One. 18(12)	e0295235.	2023	
Kurasawa S, Ya suda Y, Kato S, Maruyama S, Okada H, Kash ihara N, Narit a I, Wada T, amagata K; REA CH-J CKD colla borators.	Relationship betwee n the lower limit os f systolic blood pr essure target and k idney function decl ine in advanced chro nic kidney diseas e: an instrumental variable analysis f rom the REACH-J CKD cohort study.	Hypertens Re 46(11)	2478–2487.	2023	

Kidokoro K, Kadoya H, Cherney DZI, Kondo M, Wada Y, Umeno R, Kishi S, Nagasu H, Nagai K, Suzuki T, Sasaki T, Yamamoto M, Kanwar YS, Kashihara N.	Insights into the regulation of GFR by the Keap1-Nrf2 Pathway.	R&Kidney360.	4(10)	1454–1466.	2023	
Itano S, Kanda E, Nagasu H, Nangaku M, Kasihara N.	eGFR slope as a surrogate endpoint for clinical study in early stage of chronic kidney disease: from The Japan Chronic Kidney Disease Database.	Clin Exp Nephrol.	27(10)	847–856.	2023	
Kadoya H, Hirano A, Umeno R, Kajimoto E, Wakura T, Kondo M, Wada Y, Kido K, Nagasumi H, Sasaki T, Taniguchi S, Takahashi M, Kashihara N.	Activation of the inflammasome drives peritoneal deterioration in a mouse model of peritoneal fibrosis.	FASEB J.	37(9)	e23129.	2023	
Nangaku M, Takama H, Ichikawa T, Mukai K, Kojima M, Suzuki Y, Watada H, Wada T, Ueki K, Narita I, Kashihara N, Kadowaki T, Hase H, Akizawa T.	Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study.	Nephrol Dial Transplant.	38(5)	1204–1216.	2023	
Koshino A, Schachter M, Chertow GM, Vartanian P, Jongs P, Rossing P, Correa-Rotter R, McMurry JJ, Isidro JL, Kashihara N, Langkilde AM, Heebecker DC, Heerspink HJ.	Dapagliflozin and Anemia in Patients with Chronic Kidney Disease.	NEJM Evid.	2(6)	EVIDOa2300049.	2023	

Fujii M, Ohno Y, Ikeda A, Gohei K, Li Y, Nakamura Y, Yabe D, Tsushita K, Kashihara N, Kamide K, Kubayama M.	Current status of the rapid decline in renal function due to diabetes mellitus and its associated factors: analysis using the National Database of Health Checkups in Japan.	Hypertens Res	46(5)	1075–1089.	2023	
柏原直樹, 岸誠司, 山内佑, 山本稔也.	J-CKD-DBが解き明かすSGLT2阻害薬の腎保護効果.	糖尿病・内分泌代謝科	56(4)	386–394.	2023	
城所研吾, 柏原直樹.	腎臓病研究におけるイメージング技術の進歩を展望.	日本腎臓学会誌	65(8)	942–950.	2023	
渡邊昌, 柏原直樹.	慢性腎臓病進行をいかに予防するかThe International Workshop on Dietary Therapy for Chronic Kidney Diseaseを踏まえて.	アンチ・エイジング医学	19(5)	430–436	2023	
柏原直樹, 岸誠司, 山内佑, 山本稔也.	リアルワールドデータからみた糖尿病性腎臓病.	月刊糖尿病	15(4)	12–20.	2023	
Fukui A, Takeshi ita K, Nakashima A, Maruyama Y, Tsuboi N, Honda T, Shimohata H, Usui J, Tawara-Iida T, Ebihara I, Ishizuka T, Madyeda Y, Kobayashi H, Numajiri D, Kaneshige A, Segawa M, Yamashita M, Ohgi K, Maruyama H, Takanayasu M, Hirayama K, Kobayashi M, Yamagata K; Nishitani N, Kosaki K, Matsui M, Suga ya T, Kuro-O M, Saito C, Yamagata K, Maeda S.	The relation between proteinuria and the severity of COVID-19.	Clin Exp Nephrol.	28(3)	235–244	2024	
	Study Group of the Ibaraki Dialysis Initiation Cohort Study. NT-pro BNP level at dialysis initiation is a useful biomarker for predicting hospitalization for ischemic heart disease.	Clin Exp Nephrol.	Epub ahead of print.		2024	
	Association of Lower Extremity Muscle Strength and Function with Renal Resistance Index in Individuals with and without Chronic Kidney Disease.	Geriatrics (Basel).	8(6)	118	2023	

Mathur M, Barratt J, Chacko B, Chan TM, Kooienga L, Oh KH, Saha M, Suzuki Y, Wong MG, Yarbrough J, Xia J, Pereira BJG; ENVISION Trial Investigators Group.	A Phase 2 Trial of Sibeprenlimab in Patients with IgANephropathy.	N Engl J Med	390(1)	20-31	2024	
Okubo R, Kondo M, Imasawa T, Saito C, Kai H, Tsunoda R, Hoshino J, Watanabe T, Narita I, Matsuo S, Makino H, Hishida A, Yamagata K.	Health-related quality of life in 10 years long-term survivors of chronic kidney disease: a French study.	J Ren Nutr.	S1051-2276(23)	11:S1051-2276(23)	2023	
Writing Group for the CKD Progression Consortium; Grams ME, et al.	Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.	JAMA.	330(13)	1266-1277	2023	
Tasaki H, Eriguchi M, Yoshida H, Uemura T, Fujikata F, Nishimoto M, Kosugi T, Matsui M, Samejima KI, Iseki K, Asahi K, Yamagata K, Konta T, Fujimoto S, Narita I, Kasahara M, Shibagaki Y, Moriyama T, Kondo M, Wanabe T, Tsuruya K, Nagai K, Harada T, Mase K, Iseki K, Moriyama T, Tsuruya K, Fujimoto S, Narita I, Konta T, Kondo M, Kasahara M, Shibagaki Y, Asahi K, Wanabe T, Yamagata K.	Synergistic effect of proteinuria on the dipstick hematuria-related decline in kidney function: The Japan Specific Health Checkups (J-SHC) Study.	Clin Exp Nephrol.	Epub ahead of print.		2023	
	Weight Loss Improves Liver Dysfunction and Dipstick Proteinuria in Obesity: The Japan Specific Health Checkups Study.	JMA J.	6(3)	312-320	2023	

Takahashi-Kobayashi M, Usui J, Kawanishi K, Saito C, Ebihara I, Yamagata K.	Adding Cases to the Study of Bucillamine. Neuropathy-Associated Factor-Like Factor-Like Protein-Positive Membranous Nephropathy.	Kidney Int R8(8)	1698–1699	2023	
Kosugi T, Eriguchi M, Yoshida H, Tamaki H, Uekura T, Tasaki H, Furuyama R, Fukata F, Nishimoto M, Matsui M, Samejima KI, Iseki K, Fujimoto S, Konta T, Moriyama T, Yamagata K, Narita I, Kasahara M, Shibagaki Y, Kondo M, Asahi K, Watanabe T, Tsuruya K.	Trace proteinuria detected via dipstick test is associated with kidney function decline and new-onset overt proteinuria: the Japan Specific Health Check-ups (J-SHC) Study.	Clin Exp Nep27(10)	801–808	2023	
Kurasawa S, Yuda Y, Kato S, Maruyama S, Okada H, Kashihara N, Narita I, Wada T, Yamagata K;	REACH-J CKD collaborators. Relationships between the lower limit of systolic blood pressure target and kidney function decline in advanced chronic kidney disease: an instrumental variable analysis from the REACH-J CKD cohort study.	Hypertens RePub ahead of print.		2023	
Kosaki K, Park J, Matsui M, Sugiyama T, Kuro-O M, Saito C, Yamagata K, Maeda S.	Elevated urinary angiotensinogen excretion links central and renal hemodynamic alterations.	Sci Rep. 13(1)	11518	2023	
Calice-Silva V, Muenz D, Wong MMY, McCullough K, Charytan D, Reichel H, Robins B, Stengel B, Massy ZA, Pecoits-Filho R; CKDopps Investigators.	International practice patterns of dyslipidemia management in patients with chronic kidney disease under nephrology care: is it time to review guideline recommendations?	Lipids Health Dis. 22(1)	67	2023	

Murano H, Inoue S, Sato K, Saito M, Igarashi A, Fujimoto S, Iseki K, Moriyama T, Shibagaki Y, Kasahara M, Narita I, Yamagata K, Tsuruya K, Kondo M, Asahi K, Watanabe T, Konta T, Watanabe M.	The effect of life style on the mortality associated with respiratory disease in the general population.	Sci Rep.	13(1)	8272	2023
蒲澤 佳子、伊藤 由美、田中 純太、成田 一衛	大規模コホート追跡による慢性腎臓病 (CKD) の生活習慣リスク因子の解明	新潟県医師会報	877	7-8	2023
Wakasugi M, Yokoseki A, Wada M, Momotsu T, Saito K, Kawashima H, Nakamura K, Onodera O, Narita I.	Vegetable and Fruit Intake Frequency and Mortality in Patients With and Without Chronic Kidney Disease: A Hospital-Based Cohort Study.	J Ren Nutr.	33(4)	566-74.	2023
Wakasugi M, Narita I.	Trends in the incidence of renal replacement therapy by type of primary kidney disease in Japan, 2006–2020.	Nephrology (Carlton)	28(2)	119-29	2023
Wakasugi M, Narita I.	Birth cohort effects in incident renal replacement therapy in Japan, 1982–2021.	Clin Exp Nephrol.	27(8)	707-14	2023
Shirai N, Yamamoto S, Osawa Y, Tsubaki A, Morishita S, Narita I.	Dynamic and static balance functions in hemodialysis patients and non-dialysis dependent CKD patients.	Ther Apher Dial	27(3)	412-8	2023
Sato Y, Kabasawa K, Ito Y, Tsugane S, Nakamura K, Tanaka J, Narita I.	Association between Physical Activity in Rural Life and Sarcopenia in Community-Dwelling Middle-Aged and Older Japanese Adults: A Cross-Sectional Study.	Tohoku J Exp Med.	261(4)	317-23	2023

Otaki Y, Watanabe T, Watanabe M, Fujimoto S, Sato Y, Asahi K, Yamagata K, Tsuruya K, Narita I, Kasahara M, Shigasaki Y, Iseki K, Moriyama T, Kondo M, Watanabe T.	A Body Shape Index and Aortic Disease Related Mortality in Japanese General Population.	J Atherosclerosis Thromb.	30(7)	754–66	2023	
Okubo R, Kondo M, Imasawa T, Saito C, Kai H, Tsunoda R, Hoshino J, Watanabe T, Narita I, Matsuo S, Makino H, Hishida A, Yamagata K.	Health-related Quality of Life in 10 years Long-term Survivors of Chronic Kidney Disease: A From the REACH-J Study.	J Ren Nutr.			2023	
Kurasawa S, Yasuda Y, Kato S, Maruyama S, Okada H, Kashihara N, Narita I, Watanabe K.	Relationship between the lower limit of systolic blood pressure target and kidney function decline in advanced chronic kidney disease: an instrumental variable analysis from the REACH-J CKD cohort study.	Hypertens Res.	46(11)	2478–87.	2023	
Kosugi T, Eriguchi M, Yoshida H, Uemura T, Tasaki H, Fukata F, Nishimoto M, Matsui M, Samejima KI, Iseki K, Fujimoto S, Konta T, Moriyama T, Yamagata K, Ichiei N, Kasahara M, Shigasaki Y, Kondo M, Asahi K, Watanabe T, Tsuruya K.	Height loss is associated with decreased kidney function: The Japan Specific Health Checkups (J-SHC) Study.	Geriatr Gerontol Int.	23(4)	282–8.	2023	
Iwasaki T, et al.	Association between height loss and mortality in the general population.	Sci Rep.	13(1)	3	359	2023
Shirai N, Yamamoto S, Osawa Y, Tsubaki A, Morishita S, Sugihara T, Narita T.	Low muscle strength and physical function contribute to falls in hemodialysis patients, but not muscle mass.	Clin Exp Nephrol.	28(1)	67–74	2024	

Kitabayashi K, Yamamoto S, Narita I.	Appropriate Anthropometric Indices for Geriatric Nutritional Risk Index in Predicting Mortality in Older Japanese Patients: A Comparison of the Lorentz Formula and Body Mass Index.	Tohoku J Exp Med.			2024
Kabasawa H, Hosojima M, Narita I.	Questionnaire survey of the frequency of dietary intake during hemodialysis and the impact of COVID-19 in Japan.	Clin Exp Nephrol	28(3)	254–60.	2024
Wakasugi M, Narita I.	Higher participation rates for specific health checkups are associated with a lower incidence of treated ESKD in Japan.	Clin Exp Nephrol.	doi: 10.1007/s10157-023-02412-3.	Epub ahead of print.	2023
Wakasugi M, Narita I.	Trends in the Incidence of Renal Replacement Therapy due to Rapidly Progressive Glomerulonephritis in Japan, 2006–2021	Intern Med	doi: 10.2169/internmed.3343–23	Epub ahead of print.	2024
若杉 三奈子, 成田 一衛.	健康診断データを活用した地域レベルでのCKD 患者数の推計.	日腎会誌	65(5)	485–490	2023
若杉 三奈子, 成田 一衛.	腎硬化症による透析導入患者は、導入年末時での脳出血既往・喫煙率・過体重割合が高い	日腎会誌	65(8)	975–987	2023
若杉 三奈子, 成田 一衛.	近年の透析導入率の変化, 2006～2021.	日腎会誌	66(1)	333–342.	2024
猪阪 善隆	日本のCKD患者数の概算	日本医師会雑誌	7	In press	2024
Onishi Y, Uchida HA, Maeshima Y, Okuyama Y, Otake N, Ujike H, Tanaka K, Tsuchiuchi H, Tsuji K, Kitagawa M, Tanabe K, Morinaga H, Kinomura M, Kitamura S, Sugiyama H, Ota K, Maruyama K, Hiramatsu	The Effect of Medical Cooperation in the CKD Patients: 10-Year Multicenter Cohort Study.	J Pers Med.	13(4)	582	2023 Mar 26

Osakabe Y, Taniuchi Y, Hamada Ode K, Shimamura Y, Inotani S, Nishikawa H, Matsumoto T, Horino T, Fujimoto S, Terada Y.	Clinical significance of amphiregulin in patients with chronic kidney disease.	Clin Exp Nephrol.	doi: 10.1007/s10157-023-02445-8.	Online ahead of print.	2024
Horino T, Osaka be Y, Ishihara M, Nakajima K, Terada Y.	Nephrotic syndrome caused by IgA vasculitis flare up following COVID-19 vaccination.	QJM	116(7)	556–558	2023
Hatakeyama Y, Horino T, Yasui S, Komori M, Terada Y.	Incidence of acute kidney injury and decreased estimated glomerular filtration rate according to the site of cancer.	Clin Exp Nephrol.	27(3)	262–271	2023
Hara A, et al; LICENSE study group	Effect of Low-Density Lipoprotein Apheresis on Quality of Life in Patients with Diabetes, Proteinuria, and Hypercholesterolemia	Blood Purif	52(4)	373–381	2023
Miyasato Y, Han na RM, Mukoyama M, et al.	Associations of interdialytic weight gain in the long intervals with mortality and residual kidney function decline.	Hemodial Int	27 (3)	326–338	2023
Fujimoto D, Kuwabara T, Mukoya ma M.	Need to continue or discontinue RAS inhibitors as CKD stage advances? Any alternative?	Hypertens Res	46 (8)	2048–2050	2023
Miyasato Y, Mukoyama M.	More delicate blood pressure management in patients with chronic kidney disease: is lower not the better?	Hypertens Res	46 (12)	2757–2758	2023
Mukoyama M, Kuwabara T.	Pre-dialysis blood pressure and cardiovascular mortality in Japan: need for much stricter control?	Hypertens Res	47 (3)	811–812	2024

					In press
Yamamoto T, Katsuhiko sahara M, Muko yama M, et al.	Multicenter randomized controlled trial of intensive uric acid lowering therapy for CKD patients with hyperuricemia: TARGET-UA	Clin Exp Nephrol			
栗原孝成、向山政志	ARNI (サクビトリルバルサルタン) の高血圧治療戦略における位置づけ。	カレントテラピー	41(5)	470–475	2023
栗原孝成	総説「がん薬物療法時の腎障害診療ガイドライン2022」の概説	日本病院薬剤師雑誌	59(9)	940–943	2023
國友理恵, 要伸也	透析導入直後に現れるやさしい症状とその治療は?	月間薬事	65(12)	2405–2406	2023
Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S.	Inpatient multidisciplinary care can prevent deterioration of renal function in patients with chronic kidney disease: a nationwide cohort study.	Front Endocrinol (Lausanne)	14	1180477	2023
Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S.	Effectiveness and current status of multidisciplinary care for patients with chronic kidney disease in Japan: a nationwide multicenter cohort study.	Clin Exp Nephrol	27(6)	528–541	2023
Abe M, Hatta T, Imamura Y, Sakurada T, Kaname S.	Examine the optimal multidisciplinary care teams for patients with chronic kidney disease from a nationwide cohort study.	Kidney Res Clin Pract			In press